Ravi Varsha, Shamim Uzma, Khan Md Abuzar, Swaminathan Aparna, Mishra Pallavi, Singh Rajender, Bharali Pankaj, Chauhan Nar Singh, Pandey Rajesh
Division of Immunology and Infectious Disease Biology, INtegrative GENomics of HOst-PathogEn (INGEN-HOPE) Laboratory, CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), Delhi, India.
CSIR-Central Drug Research Institute, (CSIR-CDRI), Lucknow, Lucknow, India.
Front Med (Lausanne). 2024 Jan 15;10:1294699. doi: 10.3389/fmed.2023.1294699. eCollection 2023.
Recombination serves as a common strategy employed by RNA viruses for their genetic evolution. Extensive genomic surveillance during the COVID-19 pandemic has reported SARS-CoV-2 Recombinant strains indicating recombination events during the viral evolution. This study introspects the phenomenon of genome recombination by tracing the footprint of prominent lineages of SARS-CoV-2 at different time points in the context of on-going evolution and emergence of Recombinants.
Whole genome sequencing was carried out for 2,516 SARS-CoV-2 (discovery cohort) and 1,126 (validation cohort) using nasopharyngeal samples collected between the time period of March 2020 to August 2022, as part of the genomic surveillance program. The sequences were classified according to the different lineages of SARS-CoV-2 prevailing in India at respective time points.
Mutational diversity and abundance evaluation across the 12 lineages identified 58 Recombinant sequences as harboring the least number of mutations ( = 111), with 14 low-frequency unique mutations with major chunk of mutations coming from the BA.2. The and trends of mutations highlight the loss of mutations in the Recombinants that were associated with the SARS-CoV-2 replication efficiency, infectivity, and disease severity, rendering them functionally with low infectivity and pathogenicity. Linkage disequilibrium (LD) analysis revealed that mutations comprising the LD blocks of BA.1, BA.2, and Recombinants were found as minor alleles or as low-frequency alleles in the LD blocks from the previous SARS-CoV-2 variant samples, especially Pre-VOC. Moreover, a dissipation in the size of LD blocks as well as LD decay along with a high negative regression coefficient (R squared) value was demonstrated in the Omicron and BA.1 and BA.2 lineages, which corroborated with the breakpoint analysis.
Together, the findings help to understand the evolution and emergence of Recombinants after the Omicron lineages, for sustenance and adaptability, to maintain the epidemic spread of SARS-CoV-2 in the host population already high in immunity levels.
重组是RNA病毒用于基因进化的常见策略。在新冠疫情期间进行的广泛基因组监测报告了新冠病毒重组毒株,表明病毒进化过程中发生了重组事件。本研究通过追踪新冠病毒在不同时间点的主要谱系足迹,结合正在进行的进化和重组体的出现,对基因组重组现象进行反思。
作为基因组监测计划的一部分,使用2020年3月至2022年8月期间采集的鼻咽样本,对2516株新冠病毒(发现队列)和1126株(验证队列)进行全基因组测序。这些序列根据印度在各个时间点流行的新冠病毒不同谱系进行分类。
对12个谱系的突变多样性和丰度评估确定了58个重组序列,其突变数量最少(=111),有14个低频独特突变,大部分突变来自BA.2。突变的 和 趋势突出了重组体中与新冠病毒复制效率、传染性和疾病严重程度相关的突变缺失,使其在功能上具有低传染性和致病性。连锁不平衡(LD)分析显示,构成BA.1、BA.2和重组体LD块的突变在前一个新冠病毒变异株样本(尤其是VOC前)的LD块中被发现为次要等位基因或低频等位基因。此外,在奥密克戎、BA.1和BA.2谱系中,LD块大小的消散以及LD衰减以及高负回归系数(R平方)值得到了证实,这与断点分析一致。
总之,这些发现有助于理解奥密克戎谱系之后重组体的进化和出现,以维持生存和适应性,在宿主人群免疫水平已经很高的情况下维持新冠病毒的流行传播。